var title_f9_20_9536="PIE with extension";
var content_f9_20_9536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary interstitial emphysema with extension to multiple extrapulmonary sites in a newborn infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note pneumomediastinum, pneumopericardium, left pneumothorax, and subcutaneous emphysema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9536=[""].join("\n");
var outline_f9_20_9536=null;
var title_f9_20_9537="Patient information: Hyponatremia (The Basics)";
var content_f9_20_9537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hyponatremia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hyponatremia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H109592455\">",
"      <span class=\"h1\">",
"       What is hyponatremia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hyponatremia is the medical term for &ldquo;too little sodium.&rdquo; In people with this condition, the body holds on to too much water. That dilutes the amount of sodium in their blood. &nbsp;",
"     </p>",
"     <p>",
"      Sodium is one of many substances called &ldquo;electrolytes&rdquo; that help carry electrical signals between cells. That&rsquo;s important because many cells rely on electrical signals to work right. Sodium also helps keep the right amount of fluid inside cells.",
"     </p>",
"     <p>",
"      Symptoms of hyponatremia include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Confusion or trouble thinking clearly",
"       </li>",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"       <li>",
"        Feeling restless or irritable",
"       </li>",
"       <li>",
"        Muscle weakness, spasms or cramps",
"       </li>",
"       <li>",
"        Seizures or passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hyponatremia can also cause more serious problems, such as brain swelling and nerve damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109592448\">",
"      <span class=\"h1\">",
"       What causes hyponatremia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hyponatremia happens when the body holds onto too much water. This can happen because of:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Certain medical conditions that cause your body to hold onto too much water. These include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Heart failure, a type of heart disease in which the heart cannot pump as well as it should",
"       </li>",
"       <li>",
"        Cirrhosis, a severe form of liver disease",
"       </li>",
"       <li>",
"        Kidney disease",
"       </li>",
"       <li>",
"        Lung disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Some medicines, including a diuretic called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?10/20/10565?source=see_link\">",
"         hydrochlorothiazide",
"        </a>",
"        (HCTZ), which makes you urinate a lot",
"       </li>",
"       <li>",
"        Drinking too much water. This can happen to:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Athletes who do intense exercise (such as run marathons) and drink too much water",
"       </li>",
"       <li>",
"        People who use the drug ecstasy (ecstasy can make you feel thirsty and drink too much)",
"       </li>",
"       <li>",
"        People who are mentally ill and feel as though they cannot get enough to drink",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood loss (for example, after an injury)",
"       </li>",
"       <li>",
"        Long-lasting, severe vomiting or diarrhea (this causes your body to lose fluids and sodium)",
"       </li>",
"       <li>",
"        Poor diet",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109592441\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need blood and urine tests to get diagnosed with hyponatremia. You might also need other tests depending on your age, other symptoms, and individual situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109592434\">",
"      <span class=\"h1\">",
"       How is hyponatremia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your hyponatremia. If your hyponatremia is caused by another medical problem, such as heart failure, your doctor or nurse will want to treat that, too. &nbsp;",
"     </p>",
"     <p>",
"      Treatments might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Limiting the amount of fluid you drink",
"       </li>",
"       <li>",
"        Eating salt tablets or getting a salt-water solution into a vein",
"       </li>",
"       <li>",
"        Taking medicines that block the hormone that tells the kidneys to hold onto water",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/20/9537?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16938 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9537=[""].join("\n");
var outline_f9_20_9537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109592455\">",
"      What is hyponatremia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109592448\">",
"      What causes hyponatremia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109592441\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109592434\">",
"      How is hyponatremia treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9538="Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes";
var content_f9_20_9538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/20/9538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/20/9538/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/20/9538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/20/9538/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/20/9538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/20/9538/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/20/9538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 27-year-old male graduate student is referred by his university health service clinician for management of type 1 diabetes.",
"   </p>",
"   <p>",
"    At age 12 years, the patient was hospitalized for inability to walk, found to be in diabetic ketoacidosis (DKA), and started on insulin. He has had no other episodes of DKA. He checks his capillary blood glucose level about five times a day, but does not keep a diary. He takes glargine insulin 26 units at 11 pm daily and doses of lispro insulin four times daily. He describes his blood glucose values and lispro insulin doses as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80849 \" href=\"UTD.htm?8/41/8859\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    He reports headaches and weakness with low blood glucose readings almost daily but denies sweating, tremulousness, palpitations or syncope. These symptoms and low blood glucose values can occur at any time of day depending on food intake and insulin dose. He does not eat breakfast. His first meal of the day, at noon, is typically two sandwiches and a glass of fruit juice. Dinner at 6 pm is typically three ounces of meat, a vegetable, soup, and two red bliss potatoes. He snacks frequently and variably in the evenings.",
"   </p>",
"   <p>",
"    The hemoglobin A1C (HbA1c) was 5.80 percent six weeks ago and 5.90 percent three months ago. He weighs 160 pounds (72.7 kilograms) with a body mass index of 23. What is your assessment and plan?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is in excellent control based on his A1C levels, at which some hypoglycemia is to be expected. Since the symptoms are minimal, you advise him to eat breakfast and caution him about the danger of taking lispro insulin at 7 am without eating. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a1?source=see_link\">",
"       \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient may be having frequent episodes of hypoglycemia with hypoglycemia unawareness. He needs to eat breakfast, to keep a written diary and to learn to count carbohydrates. You reduce the dose of glargine insulin to 20 units at bedtime and reduce the dose of lispro insulin before lunch to 10 units and the dose of lispro before dinner to 12 units. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a2?source=see_link\">",
"       \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      His primary issue at age 27 is cardiovascular disease prevention. He needs a statin, a beta-adrenergic blocking agent, an angiotensin-converting enzyme inhibitor and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a3?source=see_link\">",
"       \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A3\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4136 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9538=[""].join("\n");
var outline_f9_20_9538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/4136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/4136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/41/8859\" title=\"table 1\">",
"      Lispro insulin and blood glucose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a1?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a2?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?9/20/9538-a3?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9539="Coccidioidomycosis silver stain";
var content_f9_20_9539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph of a silver stained slide showing multiple organisms of Coccidioides spp. Some spherules contain multiple small endospores (arrow). Large empty spherules can resemble the round yeast of Blastomyces dermatitidis, but the spherules of coccidioides tend to be larger, lack basophilic nuclei, and do not bud.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9539=[""].join("\n");
var outline_f9_20_9539=null;
var title_f9_20_9540="Nicotinamide (niacinamide): Patient drug information";
var content_f9_20_9540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nicotinamide (niacinamide): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     see \"Nicotinamide (niacinamide): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692165",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This vitamin is used to stop or treat niacin deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to niacin, niacinamide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol use may cause more flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698093",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Taking aspirin or ibuprofen 30 minutes before taking this drug may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid hot drinks when it is time to take this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11400 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9540=[""].join("\n");
var outline_f9_20_9540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027845\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027844\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027849\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027850\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027852\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027847\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027848\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027853\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027854\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=related_link\">",
"      Nicotinamide (niacinamide): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9541="Ethotoin: Patient drug information";
var content_f9_20_9541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethotoin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/17/6421?source=see_link\">",
"     see \"Ethotoin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Peganone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10381044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethotoin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after a meal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11944 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9541=[""].join("\n");
var outline_f9_20_9541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168814\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10381044\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018366\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018365\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018370\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018371\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018373\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018368\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018369\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018374\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018375\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/17/6421?source=related_link\">",
"      Ethotoin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9542="Iron dextran: Pediatric drug information";
var content_f9_20_9542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iron dextran: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"    see \"Iron dextran: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/15/33012?source=see_link\">",
"    see \"Iron dextran: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexferrum&reg;;",
"     </li>",
"     <li>",
"      INFeD&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexiron&trade;;",
"     </li>",
"     <li>",
"      Infufer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1020277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (Dexferrum&reg;, INFeD&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering",
"     </b>",
"     ; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anemia of prematurity: 0.2-1 mg/kg/day or 20 mg/kg/week with epoetin alfa therapy",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1020308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"      see \"Iron dextran: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering",
"     </b>",
"     ; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Iron deficiency anemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M. (INFeD&reg;), I.V. (Dexferrum&reg;, INFeD&reg;): Test dose (given 1 hour prior to starting iron dextran therapy):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &lt;10 kg: 10 mg (0.2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 10-20 kg: 15 mg (0.3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;20 kg, Adolescents, and Adults: 25 mg (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Total replacement dosage of iron dextran for iron deficiency anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     (mL) = 0.0442 x LBW (kg) x (Hb",
"     <sub>",
"      n",
"     </sub>",
"     - Hb",
"     <sub>",
"      o",
"     </sub>",
"     ) + [0.26 x LBW (kg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     LBW = lean body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hb",
"     <sub>",
"      n",
"     </sub>",
"     = desired hemoglobin (g/dL) = 12 if &lt;15 kg or 14.8 if &gt;15 kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hb",
"     <sub>",
"      o",
"     </sub>",
"     = measured hemoglobin (g/dL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute blood loss; total iron replacement dosage:",
"     </b>",
"     Assumes 1 mL of normocytic, normochromic red cells = 1 mg elemental iron",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Iron dextran (mL) = 0.02 x blood loss (mL) x hematocrit (expressed as a decimal fraction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Total dose infusions have been used safely and are the preferred method of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: Maximum daily dose: Injected in daily or less frequent increments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &lt;5 kg: 25 mg (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 5-10 kg: 50 mg (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;10 kg and Adults: 100 mg (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anemia of chronic renal failure:",
"     </b>",
"     I.V.: National Kidney Foundation DOQI Guidelines:",
"     <b>",
"      Note:",
"     </b>",
"     Initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent.  See Reference Range for target levels.  There is insufficient evidence to recommend I.V. iron if ferritin level &gt;500 ng/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children: Predialysis or peritoneal dialysis: As a single dose repeated as often as necessary:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;10 kg:  125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10-20 kg: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;20 kg:  500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children: Hemodialysis: Given during each dialysis for 10 doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;10 kg:  25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10-20 kg:  50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;20 kg:  100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults:  Initial: 100 mg at every dialysis for 10 doses; maintenance: 25-100 mg once, twice, or three times/week for 10 weeks (should provide 250-1000 mg total dose within 12 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cancer-associated anemia:",
"     </b>",
"     Adults: I.V.: 25 mg slow I.V. push test dose, followed 1 hour later by 100 mg over 5 minutes; larger doses, up to total dose infusion (over several hours) may be administered",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexferrum&reg;: Elemental iron 50 mg/mL (1 mL, 2 mL) [high-molecular-weight iron dextran]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INFeD&reg;: Elemental iron 50 mg/mL (2 mL) [low-molecular-weight iron dextran]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1020312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Avoid dilution in dextrose due to an increased incidence of local pain and phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Use Z-track technique for I.M. administration (deep into the upper outer quadrant of buttock); alternate buttocks with subsequent injections; administer test dose at same recommended site using the same technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse test dose over at least 30 seconds (INFeD&reg;) or 5 minutes (Dexferum&reg;); may be injected undiluted at a rate not to exceed 50 mg/minute; dilute large or total replacement doses in NS (50-100 mL), maximum concentration 50 mg/mL and infuse over 1-6 hours at a maximum rate of 50 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1020301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed: Compatible:",
"     </b>",
"     Cyanocobalamin, netilmicin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1020297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Variable stability reported in parenteral nutrition solution. Stable for 48 hours at room temperature in neonatal parenteral nutrition solution containing at least 2% protein (Mayhew, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1020278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of iron deficiency when oral iron administration is infeasible or ineffective (FDA approved in children &ge;4 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexferrum&reg; may be confused with Desferal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Iron dextran complex may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse event risk is reported to be higher with the high-molecular-weight iron dextran formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, chest pain, chest tightness, cyanosis, flushing, hyper-/hypotension, shock, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, disorientation, dizziness, fever, headache, malaise, seizure, unconsciousness, unresponsiveness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (cellulitis, inflammation, pain, phlebitis, soreness, swelling), muscle atrophy/fibrosis (with I.M. injection), skin/tissue staining (at the site of I.M. injection), sterile abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis/arthritis exacerbation, back pain, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, respiratory arrest, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions (sudden respiratory difficulty, cardiovascular collapse), diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Angioedema, tumor formation (at former injection site)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1020281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the iron formulation or any component; any anemia not associated with iron deficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5273877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with histories of significant allergies, asthma, serious hepatic impairment, pre-existing cardiac disease (may exacerbate cardiovascular complications), and rheumatoid arthritis (may exacerbate joint pain and swelling); avoid use during acute kidney infection. Discontinue oral iron prior to initiating parenteral iron therapy. Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation. Intramuscular injections of iron-carbohydrate complexes may have a risk of delayed injection site tumor development. Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram negative sepsis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In patients with chronic kidney disease (CKD) requiring iron supplementation, the I.V. route is preferred for hemodialysis patients; either oral iron or I.V. iron may be used for nondialysis and peritoneal dialysis CKD patients. In patients with cancer-related anemia (either due to cancer or chemotherapy-induced) requiring iron supplementation, the I.V. route is superior to oral therapy; I.M. administration is not recommended for parenteral iron supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1020282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deaths associated with parenteral iron administration following anaphylactic-type reactions have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; treatment agents for anaphylactic reactions (eg, epinephrine, steroids, diphenhydramine) should be immediately available; a test dose is recommended prior to initial therapy; however, anaphylactic and other hypersensitivity reactions have occurred after uneventful test doses. The full risk of hypersensitivity reactions, including anaphylaxis with iron dextran products, is unknown and variable among the products; a history of drug allergy or concomitant ACE inhibitor therapy has been shown to increase risk. Iron dextran products are available in two chemical formulations that are not clinically interchangeable; a high-molecular-weight formulation (DexFerrum&reg;) and a low-molecular-weight (INFeD&reg;). Adverse events (including life-threatening) associated with iron dextran usually occur more with the high-molecular-weight formulation (DexFerrum&reg;) compared to the low-molecular-weight (INFeD&reg;) (Chertow, 2006). Rapid I.V. administration is associated with flushing; fatigue; weakness; hypotension; and chest, back, groin, or flank pain. Delayed (1-2 days) infusion reaction, including sweating, urticaria, arthralgia, back pain, chills, dizziness, and fever, may occur with large doses (eg, total dose infusion) of I.V. iron dextran; usually subsides within 3-4 days. May also occur (less commonly) with I.M. administration; subsiding within 3-7 days. Use parenteral iron only in patients where the iron deficient state is not amenable to oral iron therapy; only INFeD&reg; is approved for I.M. administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6792945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. It is not known if iron dextran (as iron dextran) crosses the placenta. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1020316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs and other symptoms of anaphylactoid reactions (during I.V. infusion); reticulocyte count, serum ferritin, hemoglobin, serum iron concentrations, and transferrin saturation (TSAT). Ferritin and TSAT may be inaccurate if measured within 14 days of receiving a large single dose (1000 mg in adults).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1020304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Male: 75-175 mcg/dL; female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Percent transferrin saturation (TSAT): 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines, 2007) to maintain Hgb 11-12 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:  Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1020302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces iron found in hemoglobin, myoglobin, and specific enzymes; allows transportation of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5273507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks; serum ferritin peak: 7-9 days after I.V. dose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1020305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: 60% absorbed after 3 days; 90% after 1-3 weeks, the balance is slowly absorbed over months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Following I.V. doses, the uptake of iron by the reticuloendothelial system appears to be constant at about 40-60 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: By the reticuloendothelial system and excreted in urine and feces (via bile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5275320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron storage may lag behind the appearance of normal red blood cell morphology; use periodic hematologic determination to assess therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Auerbach M, Ballard H, Trout JR, et al, \"Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(7):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/1505177/pubmed\" id=\"1505177\" target=\"_blank\">",
"        1505177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Auerbach M, Witt D, and Toler W, &ldquo;Clinical Use of the Total Dose Intravenous Infusion of Iron Dextran,&rdquo;",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1988, 111(5):566-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/3361236/pubmed\" id=\"3361236\" target=\"_blank\">",
"        3361236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benito RP and Guerrero TC, &ldquo;Response to a Single Intravenous Dose Versus Multiple Intramuscular Administration of Iron Dextran Complex: A Comparative Study,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1973, 15(7):373-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/4198298/pubmed\" id=\"4198298\" target=\"_blank\">",
"        4198298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, et al, \"Update on Adverse Drug Events Associated With Parenteral Iron,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(2):378-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/16286429/pubmed\" id=\"16286429\" target=\"_blank\">",
"        16286429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friel JK, Andrews WL, Hall MS, et al, \"Intravenous Iron Administration to Very-Low-Birth-Weight Newborns Receiving Total and Partial Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 1995, 19(2):114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/7609274/pubmed\" id=\"7609274\" target=\"_blank\">",
"        7609274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):471-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/17720528/pubmed\" id=\"17720528\" target=\"_blank\">",
"        17720528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayhew SL and Quick MW, \"Compatibility of Iron Dextran With Neonatal Parenteral Nutrient Solutions,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(5):570-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9542/abstract-text/9066869/pubmed\" id=\"9066869\" target=\"_blank\">",
"        9066869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 3.2009.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13057 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9542=[""].join("\n");
var outline_f9_20_9542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708946\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184543\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184544\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020277\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443752\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020308\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184507\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020312\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020301\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020297\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020278\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184566\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020281\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5273877\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020282\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299544\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184516\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184519\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6792945\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020316\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020304\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020302\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5273507\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020305\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275320\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=related_link\">",
"      Iron dextran: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/15/33012?source=related_link\">",
"      Iron dextran: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9543="Butorphanol: Drug information";
var content_f9_20_9543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butorphanol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/54/2917?source=see_link\">",
"    see \"Butorphanol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Butorphanol&reg;;",
"     </li>",
"     <li>",
"      PMS-Butorphanol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Analgesic, Opioid Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention. Butorphanol has an analgesic ceiling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     Initial: 2 mg, may repeat every 3-4 hours as needed; usual range: 1-4 mg every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial: 1 mg, may repeat every 3-4 hours as needed; usual range: 0.5-2 mg every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (spray)",
"     </i>",
"     (includes use for migraine headache pain): Initial: 1 spray (~1 mg per spray) in 1 nostril; if adequate pain relief is not achieved within 60-90 minutes, an additional 1 spray in 1 nostril may be given; may repeat initial dose sequence in 3-4 hours after the last dose as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternatively, an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent (in the event drowsiness or dizziness occurs); additional 2 mg doses should not be given for 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In some clinical trials, an initial dose of 2 mg (as 2 doses 1 hour apart or 2 mg initially - 1 spray in each nostril) has been used, followed by 1 mg in 1 hour; side effects were greater at these dosages",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"     <i>",
"      Nasal spray:",
"     </i>",
"     Refer to &ldquo;moderate-to-severe pain&rdquo; indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative medication:",
"     </b>",
"     <i>",
"      I.M.:",
"     </i>",
"     2 mg 60-90 minutes before surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Supplement to balanced anesthesia:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     2 mg shortly before induction and/or an incremental dose of 0.5-1 mg (up to 0.06 mg/kg), depending on previously administered sedative, analgesic, and hypnotic medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain during labor (fetus &gt;37 weeks gestation and no signs of fetal distress):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     1-2 mg; may repeat in 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternative analgesia should be used for pain associated with delivery or if delivery is anticipated within 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial dosage should generally be",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the recommended dose; repeated dosing must be based on initial response rather than fixed intervals, but generally should be at least 6 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Nasal spray:",
"     </i>",
"     Initial dose should not exceed 1 mg; a second dose may be given after 90-120 minutes",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2676425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial dosage should generally be",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the recommended dose; repeated dosing must be based on initial response rather than fixed intervals, but generally should be at least 6 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Nasal spray:",
"     </i>",
"     Initial dose should not exceed 1 mg; a second dose may be given after 90-120 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2676426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial dosage should generally be",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the recommended dose; repeated dosing must be based on initial response rather than fixed intervals, but generally should be at least 6 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Nasal spray:",
"     </i>",
"     Initial dose should not exceed 1 mg; a second dose may be given after 90-120 minutes",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate: 1 mg/mL (1 mL); 2 mg/mL (1 mL, 2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate [preservative free]: 1 mg/mL (1 mL); 2 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as tartrate [spray]: 10 mg/mL (2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F143855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Consider avoiding simultaneous intranasal migraine sprays; may want to separate by at least 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F143902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, allopurinol, amifostine, aztreonam, bivalirudin, cefepime, cisatracurium, cladribine, dexmedetomidine, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), labetalol, linezolid, melphalan, nicardipine, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, midazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, chlorpromazine, cimetidine, diphenhydramine, droperidol, fentanyl, hydroxyzine, meperidine, methotrimeprazine, metoclopramide, midazolam, morphine, pentazocine, prochlorperazine, promethazine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Management of moderate-to-severe pain; preoperative medication; supplement to balanced anesthesia; management of pain during labor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal spray: Management of moderate-to-severe pain, including migraine headache pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Stadol may be confused with Haldol&reg;, sotalol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (43%), dizziness (19%), insomnia (nasal spray 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (nasal spray 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, headache, lethargy, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, stomach pain, unpleasant aftertaste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, nasal irritation, pharyngitis, rhinitis, sinus congestion, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apnea, chest pain, delusions, dependence (prolonged use), depression, dysphoria, edema, hallucinations, hives, hostility, hyper-/hypotension, rash, respiratory depression, seizure, shallow breathing, speech difficulty (transient), syncope, tachycardia, vertigo, withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to butorphanol or any component of the formulation; avoid use in opiate-dependent patients who have not been detoxified, may precipitate opiate withdrawal; pregnancy (prolonged use or high doses at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sumatriptan nasal spray: Concurrent use of sumatriptan nasal spray and butorphanol nasal spray may increase risk of transient high blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precaution:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10912624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Butorphanol crosses the placenta. Apnea or respiratory distress in the newborn may occur following use during labor. Use caution if abnormal fetal heart rate patterns are present.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10912625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of butorphanol are found in breast milk (~ 4 mcg/L following a maternal dose of 8 mg/day I.M.)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Butorphanol Tartrate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $2.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Butorphanol Tartrate Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (2.5 mL): $79.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F143851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     0.7-1.5 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Beforal (CZ, PL);",
"     </li>",
"     <li>",
"      Bunol (KP);",
"     </li>",
"     <li>",
"      Busphen (KP);",
"     </li>",
"     <li>",
"      Butaro (TW);",
"     </li>",
"     <li>",
"      Butrum (IN);",
"     </li>",
"     <li>",
"      Moradol (PL);",
"     </li>",
"     <li>",
"      Stadol (JP, PH, PL);",
"     </li>",
"     <li>",
"      Verstadol (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agonist of kappa opiate receptors and partial agonist of mu opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces analgesia, respiratory depression, and sedation similar to opioids",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 5-10 minutes; I.V.: &lt;10 minutes; Nasal: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: I.M.: 0.5-1 hour; I.V.: 4-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M., I.V.: 3-4 hours; Nasal: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Nasal: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3): 776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennie RE, Boehringer LA, Dierdorf SF, et al, &ldquo;Transnasal Butorphanol Is Effective for Postoperative Pain Relief in Children Undergoing Myringotomy,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1998, 89(2):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/9710397/pubmed\" id=\"9710397\" target=\"_blank\">",
"        9710397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Commiskey S, Fan LW, Ho IK, et al, &ldquo;Butorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic on Kappa-Opioid Receptors,&rdquo;",
"      <i>",
"       J Pharmacol Sci",
"      </i>",
"      , 2005, 98(2):109-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/15942128/pubmed\" id=\"15942128\" target=\"_blank\">",
"        15942128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaver RC, Vasiljev M, Wong H, et al, &ldquo;Disposition of Parenteral Butorphanol in Man,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 1980, 8(4):230-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/6105056/pubmed\" id=\"6105056\" target=\"_blank\">",
"        6105056",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Melanson SW, Morse JW, Pronchik DJ, et al, &ldquo;Transnasal Butorphanol in the Emergency Department Management of Migraine Headache,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1997, 15(1):57-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/9002572/pubmed\" id=\"9002572\" target=\"_blank\">",
"        9002572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson KE and Eisenach JC, &ldquo;Intravenous Butorphanol, Meperidine, and Their Combination Relieve Pain and Distress in Women in Labor,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2005, 102(5):1008-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/15851889/pubmed\" id=\"15851889\" target=\"_blank\">",
"        15851889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pachter IJ and Evens RP, &ldquo;Butorphanol,&rdquo;",
"      <i>",
"       Drug Alcohol Depend",
"      </i>",
"      , 1985, 14(3-4):325-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/3888579/pubmed\" id=\"3888579\" target=\"_blank\">",
"        3888579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsey R, Higbee M, Maesner J, et al, &ldquo;Influence of Age on the Pharmacokinetics of Butorphanol,&rdquo;",
"      <i>",
"       Acute Care",
"      </i>",
"      , 1986, 12(Suppl 1):8-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/3344601/pubmed\" id=\"3344601\" target=\"_blank\">",
"        3344601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shyu WC, Morgenthien EA, and Barbhaiya RH, &ldquo;Pharmacokinetics of Butorphanol Nasal Spray in Patients With Renal Impairment,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1996, 41(5):397-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/8735680/pubmed\" id=\"8735680\" target=\"_blank\">",
"        8735680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Srinivas NR, Shyu WC, Upmalis D, et al, &ldquo;Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1995, 35(4):432-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/7650235/pubmed\" id=\"7650235\" target=\"_blank\">",
"        7650235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vachharajani NN, Shyu WC, Garnett WR, et al, &ldquo;The Absolute Bioavailability and Pharmacokinetics of Butorphanol Nasal Spray in Patients With Hepatic Impairment,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(3):283-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/8841151/pubmed\" id=\"8841151\" target=\"_blank\">",
"        8841151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vachharajani NN, Shyu WC, Greene DS, et al, &ldquo;The Pharmacokinetics of Butorphanol and Its Metabolites at Steady State Following Nasal Administration in Humans,&rdquo;",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1997, 18(3):191-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9543/abstract-text/9113342/pubmed\" id=\"9113342\" target=\"_blank\">",
"        9113342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9179 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9543=[""].join("\n");
var outline_f9_20_9543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143876\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143894\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143878\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143879\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676425\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676426\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143850\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143896\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143855\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143902\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143854\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143904\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143892\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143858\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143838\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298918\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143843\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143872\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143845\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912624\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143881\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912625\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143860\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143847\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143851\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143861\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143837\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143857\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/54/2917?source=related_link\">",
"      Butorphanol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9544="Aliskiren, amlodipine and hydrochlorothiazide: Drug information";
var content_f9_20_9544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aliskiren, amlodipine and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41397?source=see_link\">",
"    see \"Aliskiren, amlodipine and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11390284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11393868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amturnide&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11371550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide;",
"     </li>",
"     <li>",
"      Renin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11390345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for initial therapy. Dose is individualized; combination product may be substituted for individual components in patients currently maintained on all three agents separately, used to switch a patient on any dual combination of the components who is experiencing dose-limiting adverse reactions from an individual component (to a lower dose of that component), or used as add-on therapy in patients not adequately controlled with any two of the following: Aliskiren, dihydropyridine calcium channel blockers, and thiazide diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"     <i>",
"      Add-on/switch therapy/replacement therapy:",
"     </i>",
"     Aliskiren 150-300 mg and amlodipine 5-10 mg and hydrochlorothiazide 12.5-25 mg once daily; dose may be titrated after 2 weeks of therapy. Maximum recommended daily dose: Aliskiren 300 mg; amlodipine 10 mg; hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11390346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use of lower initial doses should be considered (use of individual components may be necessary).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11390348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: No dosage adjustment may be necessary (Vaidyanathan, 2007 [aliskiren]); however, risk of hyperkalemia and progressive renal dysfunction may occur with aliskiren; use with caution;  hydrochlorothiazide is usually ineffective when  Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and is contraindicated in patients who are anuric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD (requiring hemodialysis): Initial: No dosage adjustment may be necessary (Khadzhynov, 2012 [aliskiren]); however, risk of hyperkalemia is increased with chronic aliskiren therapy; use with extreme caution; hydrochlorothiazide is usually ineffective when  Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and is contraindicated in patients who are anuric.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11390347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Mild-to-severe: Use with caution and titrate slowly; amlodipine elimination prolonged; lower initial dose should be considered (possibly requiring use of the individual agents).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11384073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amturnide&trade;: Aliskiren 150 mg, amlodipine 5 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amturnide&trade;: Aliskiren 300 mg, amlodipine 5 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amturnide&trade;: Aliskiren 300 mg, amlodipine 5 mg, and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amturnide&trade;: Aliskiren 300 mg, amlodipine 10 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amturnide&trade;: Aliskiren 300 mg, amlodipine 10 mg, and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11390286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11390349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time daily. May take with or without a meal, but consistent administration with regard to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11371551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not for initial therapy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11390285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Amturnide&trade; may be confused with AMILoride",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11390295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Frequencies reported with combination product. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (4%), headache (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11390291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aliskiren, amlodipine, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; anuria; concomitant use with an ACE inhibitor or ARB in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11390292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with hydrochlorothiazide use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur (rarely) during monotherapy; risk may increase in patients with predisposing factors (eg, renal dysfunction, diabetes mellitus or concomitant use with ACE inhibitors, potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Anaphylaxis and angioedema have been reported. Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with caution in any patient with a history of angioedema (of any etiology) as angioedema, some cases necessitating hospitalization and intubation, has been observed (rarely) with aliskiren use. Discontinue immediately following the occurrence of anaphylaxis or angioedema; do not readminister. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Early, aggressive, and appropriate management is critical. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension may occur (rarely) with or without syncope, particularly in patients with an activated renin-angiotensin system (ie, volume or salt-depleted patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Photosensitization may occur with hydrochlorothiazide use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control. Use of aliskiren (monotherapy or combined with ACE inhibitors or ARBs) in patients with type 2 diabetes mellitus has demonstrated an increased incidence of renal impairment, hypotension, and hyperkalemia; use is contraindicated in patients with diabetes mellitus who are taking an ACE inhibitor or ARB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated with hydrochlorothiazide use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; increase the dose slowly; subtle changes in fluid and electrolyte balance from hydrochlorothiazide may precipitate hepatic coma. In patients with hepatic impairment, a lower initial dose of amlodipine should be considered (possibly requiring use of the individual agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercholesterolemia: Use hydrochlorothiazide with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypokalemia: Use hydrochlorothiazide with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution or avoid in patients with deteriorating renal function or low renal blood flow (eg, renal artery stenosis, severe heart failure); may increase risk of developing acute renal failure or hyperkalemia. Thiazide diuretics are not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute, loop diuretics are preferred over thiazides. Concomitant use of aliskiren with an ACE inhibitor or ARB may increase risk of developing acute renal failure and should be avoided in patient with GFR &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concurrent use with strong inhibitors of P-glycoprotein (eg, cyclosporine, itraconazole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Exposure to amlodipine is increased in the elderly; use of lower initial doses should be considered (may necessitate use of individual agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Other warnings/precautions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Titration: Peak antihypertensive effect is delayed; dosage titration should occur 2 weeks after a given dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11427813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aliskiren may enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Aliskiren. Canagliflozin may enhance the hypotensive effect of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Aliskiren may decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Aliskiren. Management: Avoid concomitant use of aliskiren and grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction. Monitor for decreased aliskiren levels/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11390298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: High-fat meals decrease aliskiren absorption. Grapefruit juice may modestly increase amlodipine levels. Hydrochlorothiazide may deplete potassium, sodium, and magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease amlodipine levels. Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11390287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11390288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11390289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11390290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11390305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; however, a high-fat meal reduces absorption. Consistent administration with regards to meals is recommended. Avoid salt substitutes containing potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amturnide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-5-12.5 mg (30): $107.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-5-12.5 mg (30): $136.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-5-25 mg (30): $136.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-10-12.5 mg (30): $136.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-10-25 mg (30): $136.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11390351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure; serum electrolytes, BUN, serum creatinine; assess weight, I &amp; O reports daily to determine fluid loss; peripheral edema",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11390301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Aliskiren: Direct renin inhibitor, resulting in blockade of the conversion of angiotensinogen to angiotensin I. Angiotensin I suppression decreases the formation of angiotensin II (Ang II), a potent blood pressure-elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention). Ang II also functions within the Renin-Angiotensin-Aldosterone System (RAAS) as a negative inhibitory feedback mediator within the renal parenchyma to suppress the further release of renin. Thus, reductions in Ang II levels suppress this feedback loop, leading to further increased plasma renin concentrations (PRC) and subsequent activity (PRA). This disinhibition effect can be potentially problematic for ACE inhibitor and ARB therapy, as increased PRA could partially overcome the pharmacologic inhibition of the RAAS. As aliskiren is a direct inhibitor of renin activity, blunting of PRA despite the increased PRC (from loss of the negative feedback) may be clinically advantageous. The effect of aliskiren on bradykinin levels is unknown.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amlodipine: Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hydrochlorothiazide: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11390303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Khadzhynov D, Slowinski T, Lieker I, et al, \"Pharmacokinetics of Aliskiren in Patients With End-Stage Renal Disease Undergoing Haemodialysis,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2012, 51(10):661-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9544/abstract-text/23018529/pubmed\" id=\"23018529\" target=\"_blank\">",
"        23018529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaidyanathan S, Bigler H, Yeh C, et al, &ldquo;Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskerin Alone and in Combination with Irbesartan in Renal Impairment,&rdquo; Clin Pharmacokinet, 2007, 46(8):661-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9544/abstract-text/17655373/pubmed\" id=\"17655373\" target=\"_blank\">",
"        17655373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16099 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9544=[""].join("\n");
var outline_f9_20_9544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390284\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11393868\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11371550\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390345\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390346\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390348\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390347\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11384073\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390349\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11371551\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390285\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390295\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390291\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390292\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298708\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11427813\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390298\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390287\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390288\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390289\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390290\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390305\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322882\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390351\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390301\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390303\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41397?source=related_link\">",
"      Aliskiren, amlodipine and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9545="Fludarabine: Drug information";
var content_f9_20_9545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fludarabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37525?source=see_link\">",
"    see \"Fludarabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/28/42438?source=see_link\">",
"    see \"Fludarabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fludara&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fludara&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic lymphocytic leukemia (CLL):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral (Canadian labeling; not available in U.S.): 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 days every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CLL combination regimens (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CFAR: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide, rituximab and alemtuzumab) (Wierda, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FC: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Eichhorst, 2006)",
"     <b>",
"      or",
"     </b>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Flinn, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FCR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide and rituximab) (Keating, 2005; Robak, 2010; Wierda, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FluCam: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 4-6 cycles (in combination with alemtuzumab) (Elter, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Byrd, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OFAR: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days every 28 days for 6 cycles (in combination with oxaliplatin, cytarabine, and rituximab) (Tsimberidou, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML, high-risk patients (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days induction therapy, followed by post remission therapy of 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every other cycle (in combination with cytarabine with or without filgrastim) (Borthakur, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML, refractory (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (in combination with cytarabine and filgrastim), may repeat once for partial remission (Montillo, 1998)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days for 1 or 2 cycles (in combination with cytarabine, idarubicin, and filgrastim) (Virchis, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphomas:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for 5 days every 28 days; dosage adjustment may be necessary for hematologic or nonhematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Follicular lymphoma (unlabeled use):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FCR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 21 days for 4 cycles (in combination with cyclophosphamide and rituximab) (Sacchi, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FCMR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 4 cycles (in combination with cyclophosphamide, mitoxantrone, and rituximab) (Forstpointner, 2004; Forstpointner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FND: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for up to 8 cycles (in combination with mitoxantrone and dexamethasone) (McLaughlin, 1996; Tsimberidou, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FNDR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for up to 8 cycles (in combination with mitoxantrone, dexamethasone, and rituximab) (McLaughlin, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Czuczman, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mantle cell lymphoma (unlabeled use):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FC: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4-5 days or 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3-5 days (in combination with cyclophosphamide) (Cohen, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FCMR: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days for 4 cycles (in combination with cyclophosphamide, mitoxantrone, and rituximab) (Forstpointner, 2004; Forstpointner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Waldenstron&rsquo;s macroglobulinemia (unlabeled use):",
"     </b>",
"     I.V.:25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days (Foran, 1999)",
"     <b>",
"      or",
"     </b>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Treon, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stem cell transplant (allogeneic) conditioning regimen, reduced-intensity, (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 6 doses beginning 10 days prior to transplant",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 5 days beginning 6 days prior to transplant (in combination with busulfan with or without antithymocyte globulin) (Schetelig, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stem cell transplant (allogeneic) nonmyeloablative conditioning regimen (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 3 doses beginning 5 days prior to transplant (in combination with cyclophosphamide and rituximab) (Khouri, 2008)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 3 doses beginning 4 days prior to transplant (in combination with total body irradiation) (Rezvani, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/28/42438?source=see_link\">",
"      see \"Fludarabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML (unlabeled use):",
"     </b>",
"     I.V.: 10.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 48 hours (Lange, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ALL or AML, relapsed (unlabeled use):",
"     </b>",
"     I.V.: 10.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 48 hours (Avramis, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stem cell transplant (allogeneic) conditioning regimen, reduced-intensity (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 6 doses beginning 7-10 days prior to transplant (in combination with busulfan and antithymocyte globulin) (Pulsipher, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Adults: CLL: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute: Decrease dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Decrease dose to 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     CLL (Oral, I.V.), NHL (I.V.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-70 mL/minute: Reduce dose by up to 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians: Aronoff, 2007: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 80% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 80% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6853864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic or nonhematologic toxicity (other than neurotoxicity): Consider treatment delay or dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemolysis: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neurotoxicity: Consider treatment delay or discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as phosphate: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fludara&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as phosphate [preservative free]: 25 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fludara&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablet may be administered with or without food; should be swallowed whole with water; do not chew, break, or crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Usually administered as a 30-minute infusion; continuous infusions (unlabeled administration rate) are occasionally used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F171913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, amsacrine, aztreonam, bleomycin, butorphanol, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, ceftazidime, cefuroxime, cimetidine, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dexamethasone sodium phosphate, diphenhydramine, doxorubicin, doxycycline, droperidol, etoposide, etoposide phosphate, famotidine, filgrastim, floxuridine, fluconazole, fluorouracil, furosemide, gemcitabine, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, ifosfamide, imipenem/cilastatin, lorazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, minocycline, mitoxantrone, morphine, multivitamins, nalbuphine, ondansetron, pentostatin, piperacillin, piperacillin/tazobactam, potassium chloride, promethazine, ranitidine, sodium bicarbonate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, chlorpromazine, daunorubicin HCl, ganciclovir, hydroxyzine, prochlorperazine edisylate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Treatment of progressive or refractory B-cell chronic lymphocytic leukemia (CLL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Second-line treatment of chronic lymphocytic leukemia (CLL); second-line treatment of low-grade, refractory non-Hodgkin lymphoma (NHL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F171904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of non-Hodgkin lymphomas (NHL); acute myeloid leukemia (AML), either refractory or in poor risk patients; relapsed acute lymphocytic leukemia (ALL) or AML in pediatric patients; Waldenstr&ouml;m's macroglobulinemia (WM); reduced-intensity conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (generally administered in combination with busulfan or cyclophosphamide and antithymocyte globulin or lymphocyte immune globulin, or in combination with melphalan and alemtuzumab)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fludarabine may be confused with cladribine, floxuridine, Flumadine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fludara&reg; may be confused with FUDR&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (8% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (60% to 69%), fatigue (10% to 38%), pain (20% to 22%), chills (11% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (31% to 36%), anorexia (7% to 34%), diarrhea (13% to 15%), gastrointestinal bleeding (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (nadir: 10-14 days; recovery: 5-7 weeks; dose-limiting toxicity), anemia (60%), neutropenia (grade 4: 59%; nadir: ~13 days), thrombocytopenia (55%; nadir: ~16 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (9% to 65%), myalgia (4% to 16%), paresthesia (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbance (3% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (10% to 44%), pneumonia (16% to 22%), dyspnea (9% to 22%), upper respiratory infection (2% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (33% to 44%), diaphoresis (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina (&le;6%), arrhythmia (&le;3%), cerebrovascular accident (&le;3%), heart failure (&le;3%), MI (&le;3%), supraventricular tachycardia (&le;3%), deep vein thrombosis (1% to 3%), phlebitis (1% to 3%), aneurysm (&le;1%), transient ischemic attack (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise (6% to 8%), headache (&le;3%), sleep disorder (1% to 3%), cerebellar syndrome (&le;1%), depression (&le;1%), mentation impaired (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (&le;3%), pruritus (1% to 3%), seborrhea (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1% to 6%), dehydration (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (&le;9%), esophagitis (&le;3%), constipation (1% to 3%), mucositis (&le;2%), dysphagia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (3% to 4%), hesitancy (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholelithiasis (&le;3%), liver function tests abnormal (1% to 3%), liver failure (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Osteoporosis (&le;2%), arthralgia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (2% to 3%), renal failure (&le;1%), renal function test abnormal (&le;1%), proteinuria (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (&le;9%), allergic pneumonitis (&le;6%), hemoptysis (1% to 6%), sinusitis (&le;5%), bronchitis (&le;1%), epistaxis (&le;1%), hypoxia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (&le;1%), tumor lysis syndrome (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome, blindness, bone marrow fibrosis, cerebral hemorrhage, coma, Epstein-Barr virus (EBV) associated lymphoproliferation, EBV reactivation, erythema multiforme, Evans syndrome, hemolytic anemia (autoimmune), hemophilia (acquired), hemorrhagic cystitis, herpes zoster reactivation, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, interstitial pulmonary infiltrate, metabolic acidosis, myelodysplastic syndrome/acute myeloid leukemia (usually associated with prior or concurrent treatment with other anticancer agents), opportunistic infection, optic neuritis, optic neuropathy, pancytopenia, pemphigus, pericardial effusion, peripheral neuropathy, pneumonitis, progressive multifocal leukoencephalopathy (PML), pulmonary fibrosis, pulmonary hemorrhage, respiratory distress, respiratory failure, Richter&rsquo;s syndrome, seizure, skin cancer (new onset or exacerbation), Stevens-Johnson syndrome, thrombocytopenia (autoimmune), thrombocytopenic purpura (autoimmune), toxic epidermal necrolysis, trilineage bone marrow aplasia, trilineage bone marrow hypoplasia, urate crystalluria, wrist drop",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Also observed: Neurologic syndrome characterized by cortical blindness, coma, and paralysis [36% at doses &gt;96 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for 5-7 days; &lt;0.2% at doses &lt;125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle (onset of neurologic symptoms may be delayed for 3-4 weeks)]",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity of fludarabine or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); decompensated hemolytic anemia; concurrent use with pentostatin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune effects:",
"     <b>",
"      [U.S. Boxed Warning]: Life-threatening (and sometimes fatal) autoimmune effects, including hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia have occurred;",
"     </b>",
"     monitor closely for hemolysis; discontinue fludarabine if hemolysis occurs. The hemolytic effects usually recur with fludarabine rechallenge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe bone marrow suppression (anemia, thrombocytopenia, and neutropenia) may occur;",
"     </b>",
"     may be cumulative. Severe myelosuppression (trilineage bone marrow hypoplasia/aplasia) has been reported (rare) with a duration of significant cytopenias ranging from 2 months to 1 year). First-line combination therapy is associated with prolonged cytopenias, with anemia lasting up to 7 months, neutropenia up to 9 months, and thrombocytopenia up to 10 months; increased age is predictive for prolonged cytopenias (Gill, 2010). Use with caution in patients with pre-existing hematological disorders (particularly granulocytopenia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Higher than recommended doses (up to 96 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      /day for 5-7 days) are associated with severe neurologic toxicity (delayed blindness, coma, death); similar neurotoxicity (agitation, coma, confusion, seizure) has been reported with standard CLL doses.",
"     </b>",
"     Symptoms of neurotoxicity due to high doses appeared from 21-60 days following the last fludarabine dose, although neurotoxicity has been reported as early as 7 days and up to 225 days. Possible neurotoxic effects of chronic administration are unknown. Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients with pre-existing central nervous system disorder (epilepsy), spasticity, or peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) (usually fatal) due to JC virus has been reported with use; most cases were in patients who had received prior and/or other concurrent chemotherapy. Onset may be a few weeks or may be delayed up to 1 year. Evaluate any neurological change promptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: May cause tumor lysis syndrome; risk is increased in patients with large tumor burden prior to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Use with caution in patients with documented infection, fever, immunodeficiency, or with a history of opportunistic infection. Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; clearance of the primary metabolite 2-fluoro-ara-A is decreased in patients with renal impairment; dosage reductions are recommended (monitor closely for excessive toxicity); use of the I.V. formulation is not recommended if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute. Canadian labeling contraindicates use of oral and I.V. formulations if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pentostatin:",
"     <b>",
"      [U.S. Boxed Warning]: Do not use in combination with pentostatin; may lead to severe, even fatal pulmonary toxicity.",
"     </b>",
"     Concomitant use is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood products: Patients receiving blood products should only receive irradiated blood products due to the potential for transfusion related GVHD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Live vaccines: Avoid vaccination with live vaccines during and after fludarabine treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: Fludarabine may enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies. Based on the mechanism of action, fludarabine has the potential to cause fetal harm if administered during pregnancy. There are no adequate and well-controlled studies in pregnant women. Effective contraception is recommended during and for 6 months after treatment for women and men with female partners of reproductive potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5709863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fludara Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $367.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fludarabine Phosphate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $132.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, AST, ALT, serum creatinine, serum albumin, uric acid; monitor for signs of infection and neurotoxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Beneflur (ES, MX);",
"     </li>",
"     <li>",
"      Fludacel (PE);",
"     </li>",
"     <li>",
"      Fludara (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, HK, HN, HU, ID, IE, IL, IN, IT, KP, LU, MY, NL, NO, NZ, PH, PL, PY, RU, SE, SG, TH, TR, TW, UY, VE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fludarabine inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase; also inhibits DNA primase and DNA ligase I",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 38-96 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; widely with extensive tissue binding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 2-fluoro-ara-A: ~19% to 29%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: I.V.: Fludarabine phosphate is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (active metabolite), which subsequently enters tumor cells and is phosphorylated by deoxycytidine kinase to the active triphosphate derivative (2-fluoro-ara-ATP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 2-fluoro-ara-A: 50% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-fluoro-ara-A: ~20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%, 23% as 2-fluoro-ara-A) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adkins JC, Peters DH, and Markham A, &ldquo;Fludarabine. An Update of Its Pharmacology and Use in the Treatment of Haematological Malignancies,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(6):1005-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/9179529/pubmed\" id=\"9179529\" target=\"_blank\">",
"        9179529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 172.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avramis VI, Wiersma S, Krailo MD, et al, &ldquo;Pharmacokinetic and Pharmacodynamic Studies of Fludarabine and Cytosine Arabinoside Administered as Loading Boluses Followed by Continuous Infusions After a Phase I/II Study in Pediatric Patients With Relapsed Leukemias. The Children's Cancer Group,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 1998, 4(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/9516951/pubmed\" id=\"9516951\" target=\"_blank\">",
"        9516951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacigalupo A, &ldquo;Second EBMT Workshop on Reduced Intensity Allogeneic Hemopoietic Stem Cell Transplants (RI-HSCT),&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2002, 29(3):191-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/11859390/pubmed\" id=\"11859390\" target=\"_blank\">",
"        11859390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boogaerts MA, Van Hoof A, Catovsky D, et al, &ldquo;Activity of Oral Fludarabine Phosphate in Previously Treated Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(22):4252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/11709569/pubmed\" id=\"11709569\" target=\"_blank\">",
"        11709569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borthakur G, Kantarjian H, Wang X, et al, &ldquo;Treatment of Core-Binding-Factor in Acute Myelogenous Leukemia With Fludarabine, Cytarabine, and Granulocyte Colony-Stimulating Factor Results in Improved Event-Free Survival,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(11):3181-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18932257/pubmed\" id=\"18932257\" target=\"_blank\">",
"        18932257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Byrd JC, Peterson BL, Morrison VA, et al, &ldquo;Randomized Phase 2 Study of Fludarabine With Concurrent vs Sequential Treatment With Rituximab in Symptomatic, Untreated Patients With B-Cell Chronic Lymphocytic Leukemia: Results From Cancer and Leukemia Group B 9712 (CALGB 9712),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 101(1):6-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/12393429/pubmed\" id=\"12393429\" target=\"_blank\">",
"        12393429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen BJ, Moskowitz C, Straus D, et al, &ldquo;Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2001, 42(5):1015-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/11697618/pubmed\" id=\"11697618\" target=\"_blank\">",
"        11697618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Czuczman MS, Koryzna A, Mohr A, et al, &ldquo;Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(4):694-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/15681517/pubmed\" id=\"15681517\" target=\"_blank\">",
"        15681517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eichhorst BF, Busch R, Hopfinger G, et al, &ldquo;Fludarabine Plus Cyclophosphamide Versus Fludarabine Alone in First-Line Therapy of Younger Patients With Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(3):885-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/16219797/pubmed\" id=\"16219797\" target=\"_blank\">",
"        16219797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elter T, Borchmann P, Schulz H, et al, &ldquo;Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(28):7024-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/16145065/pubmed\" id=\"16145065\" target=\"_blank\">",
"        16145065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flinn IW, Neuberg DS, Grever MR, et al, &ldquo;Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(7):793-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/17283364/pubmed\" id=\"17283364\" target=\"_blank\">",
"        17283364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foran JM, Rohatiner AZ, Coiffier B, et al, &ldquo;Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstr&ouml;m's Macroglobulinemia, and Mantle-Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(2):546-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/10080598/pubmed\" id=\"10080598\" target=\"_blank\">",
"        10080598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forstpointner R, Dreyling M, Repp R, et al, &ldquo;The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) Significantly Increases the Response Rate and Prolongs Survival as Compared With FCM Alone in Patients With Relapsed and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group,&rdquo;",
"      <i>",
"       Blood,",
"      </i>",
"      2004, 104(10):3064-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/15284112/pubmed\" id=\"15284112\" target=\"_blank\">",
"        15284112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forstpointner R, Unterhalt M, Dreyling M, et al, &ldquo;Maintenance Therapy With Rituximab Leads to a Significant Prolongation of Response Duration After Salvage Therapy With a Combination of Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) in Patients With Recurring and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low Grade Lymphoma Study Group (GLSG),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(13):4003-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/16946304/pubmed\" id=\"16946304\" target=\"_blank\">",
"        16946304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill S, Carney D, Ritchie D, et al, &ldquo;The Frequency, Manifestations, and Duration of Prolonged Cytopenias After First-Line Fludarabine Combination Therapy,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(2):331-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/19625344/pubmed\" id=\"19625344\" target=\"_blank\">",
"        19625344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giralt S, Aleman A, Anagnostopoulos A, et al, &ldquo;Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in Patients With Multiple Myeloma,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2002, 30(6):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/12235521/pubmed\" id=\"12235521\" target=\"_blank\">",
"        12235521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagenbeek A, Eghbali H, Monfardini S, et al, &ldquo;Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(10):1590-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/16575010/pubmed\" id=\"16575010\" target=\"_blank\">",
"        16575010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson SA, &ldquo;Clinical Pharmacokinetics of Nucleoside Analogues: Focus on Haematological Malignancies,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2000, 39(1):5-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/10926348/pubmed\" id=\"10926348\" target=\"_blank\">",
"        10926348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MJ, O'Brien S, Albitar M, et al, &ldquo;Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(18):4079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/15767648/pubmed\" id=\"15767648\" target=\"_blank\">",
"        15767648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MJ, O'Brien S, McLaughlin P, et al, &ldquo;Clinical Experience With Fludarabine in Hemato-Oncology,&rdquo;",
"      <i>",
"       Hematol Cell Ther",
"      </i>",
"      , 1996, 38(Suppl 2):83-91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khouri IF, McLaughlin P, Saliba RM, et al, &ldquo;Eight-Year Experience With Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma After Nonmyeloablative Conditioning With Fludarabine, Cyclophosphamide, and Rituximab,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(12):5530-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18411419/pubmed\" id=\"18411419\" target=\"_blank\">",
"        18411419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange BJ, Smith FO, Feusner J, et al, &ldquo;Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1044-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18000167/pubmed\" id=\"18000167\" target=\"_blank\">",
"        18000167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin P, Hagemeister FB, Rodriguez MA, et al, &ldquo;Safety of Fludarabine, Mitoxantrone, and Dexamethasone Combined With Rituximab in the Treatment of Stage IV Indolent Lymphoma,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2000, 27(6 Suppl 12):37-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/11225999/pubmed\" id=\"11225999\" target=\"_blank\">",
"        11225999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin P, Hagemeister FB, Romaguera JE, et al, &ldquo;Fludarabine, Mitoxantrone, and Dexamethasone: An Effective New Regimen for Indolent Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(4):1262-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/8648382/pubmed\" id=\"8648382\" target=\"_blank\">",
"        8648382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montillo M, Mirto S, Petti MC, et al, &ldquo;Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1998, 58(2):105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/9625576/pubmed\" id=\"9625576\" target=\"_blank\">",
"        9625576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Acute Myeloid Leukemia,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Waldenstrom&rsquo;s Macroglobulinemia/Lymphoplasmacytic Lymphoma,&rdquo; Version.1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/waldenstroms.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plosker GL and Figgitt DP, \"Oral fludarabine,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(21):2317-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/14524733/pubmed\" id=\"14524733\" target=\"_blank\">",
"        14524733",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plunkett W, Gandhi V, Huang P, et al, &ldquo;Fludarabine: Pharmacokinetics, Mechanisms of Action, and Rationales for Combination Therapies,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1993, 20(5 Suppl 7):2-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pulsipher MA, Boucher KM, Wall D, et al, &ldquo;Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(7):1429-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/19528536/pubmed\" id=\"19528536\" target=\"_blank\">",
"        19528536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rezvani AR, Storer B, Maris M, et al, &ldquo;Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(2):211-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18056679/pubmed\" id=\"18056679\" target=\"_blank\">",
"        18056679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robak T, Dmoszynska A, Solal-C&eacute;ligny P, et al, &ldquo;Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(10):1756-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/20194844/pubmed\" id=\"20194844\" target=\"_blank\">",
"        20194844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossi JF, van Hoof A, de Boeck K, et al, &ldquo;Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(7):1260-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/15051774/pubmed\" id=\"15051774\" target=\"_blank\">",
"        15051774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacchi S, Pozzi S, Marcheselli R, et al, &ldquo;Rituximab in Combination With Fludarabine and Cyclophosphamide in the Treatment of Patients With Recurrent Follicular Lymphoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 110(1):121-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/17503433/pubmed\" id=\"17503433\" target=\"_blank\">",
"        17503433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schetelig J, Bornhauser M, Kiehl M, et al, &ldquo;Reduced-Intensity Conditioning With Busulfan and Fludarabine With or Without Antithymocyte Globulin in HLA-Identical Sibling Transplantation - A Retrospective Analysis,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2004, 33(5):483-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/14716342/pubmed\" id=\"14716342\" target=\"_blank\">",
"        14716342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tam CS, O'Brien S, Wierda W, et al, &ldquo;Long-Term Results of the Fludarabine, Cyclophosphamide, and Rituximab Regimen as Initial Therapy of Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(4):975-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18411418/pubmed\" id=\"18411418\" target=\"_blank\">",
"        18411418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP, Branagan AR, Ioakimidis L, et al, &ldquo;Long-Term Outcomes to Fludarabine and Rituximab in Waldenstr&ouml;m Macroglobulinemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(16):3673-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/19015393/pubmed\" id=\"19015393\" target=\"_blank\">",
"        19015393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, McLaughlin P, Younes A, et al, &ldquo;Fludarabine, Mitoxantrone, Dexamethasone (FND) Compared With an Alternating Triple Therapy (ATT) Regimen in Patients With Stage IV Indolent Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(13):4351-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/12393618/pubmed\" id=\"12393618\" target=\"_blank\">",
"        12393618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, Wierda WG, Plunkett W, et al, &ldquo;Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(2):196-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/18182662/pubmed\" id=\"18182662\" target=\"_blank\">",
"        18182662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Besien K, Devine S, Wickrema A, et al, &ldquo;Regimen-Related Toxicity After Fludarabine-Melphalan Conditioning: A Prospective Study of 31 Patients With Hematologic Malignancies,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 32(5):471-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/12942092/pubmed\" id=\"12942092\" target=\"_blank\">",
"        12942092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Virchis A, Koh M, Rankin P, et al, &ldquo;Fludarabine, Cytosine Arabinoside, Granulocyte-Colony Stimulating Factor With or Without Idarubicin in the Treatment of High Risk Acute Leukaemia of Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2004, 124(1):26-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/14675405/pubmed\" id=\"14675405\" target=\"_blank\">",
"        14675405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierda WG, O&rsquo;Brien SM, Faderl SH, et al, &ldquo;CFAR, An Active Frontline Regimen for High-Risk Patients With CLL, Including Those With Del 17p,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(11):2095 [abstract 2095 from 2008 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierda W, O'Brien S, Wen S, et al, &ldquo;Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(18):4070-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9545/abstract-text/15767647/pubmed\" id=\"15767647\" target=\"_blank\">",
"        15767647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8452 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9545=[""].join("\n");
var outline_f9_20_9545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708775\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171868\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171869\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171908\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171872\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171891\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171873\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171874\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881449\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6853864\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171848\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950041\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171833\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171851\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171913\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171849\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171904\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171916\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171906\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171854\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171837\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299343\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171842\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171865\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171844\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171856\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171880\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709863\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323155\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171846\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171857\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171836\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171853\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37525?source=related_link\">",
"      Fludarabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/28/42438?source=related_link\">",
"      Fludarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9546="Cyclophosphamide: Drug information";
var content_f9_20_9546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclophosphamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6550?source=see_link\">",
"    see \"Cyclophosphamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"    see \"Cyclophosphamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Procytox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antirheumatic, Miscellaneous;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted. Antiemetics may be recommended (emetogenic potential varies by dose and combination therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Single agent for solid tumors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 40-50 mg/kg in divided doses over 2-5 days",
"     <b>",
"      or",
"     </b>",
"     10-15 mg/kg every 7-10 days",
"     <b>",
"      or",
"     </b>",
"     3-5 mg/kg twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-5 mg/kg/day (initial and maintenance dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 40-50 mg/kg (1500-1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) administered  as 10-20 mg/kg/day over 2-5 days; Maintenance: 10-15 mg/kg (350-550 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) every 7-10 days",
"     <b>",
"      or",
"     </b>",
"     3-5 mg/kg (110-185 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial 1-5 mg/kg/day (depending on tolerance); Maintenance: 1-5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Indication specific and/or unlabeled uses/dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (unlabeled dosing): Multiple-agent regimens:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hyper-CVAD regimen:",
"     </i>",
"     I.V.: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours (with mesna) every 12 hours for 6 doses on days 1, 2, and 3 during odd-numbered cycles (cycles 1, 3, 5, 7) of an 8-cycle phase (Kantarjian, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Larson (CALGB8811) regimen:",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &lt;60 years: Induction phase: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 4-week cycle; Early intensification phase: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 4-week cycle (repeat once); Late intensification phase: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 29 of an 8-week cycle (Larson, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &ge;60 years: Induction phase: 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 4-week cycle; Early intensification phase: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 4-week cycle (repeat once); Late intensification phase: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 29 of an 8-week cycle (Larson, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer (unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      AC regimen:",
"     </i>",
"     I.V.: 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days (in combination with doxorubicin) for 4 cycles (Fisher, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CEF regimen:",
"     </i>",
"     Oral: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-14 every 28 days (in combination with epirubicin and fluorouracil) for 6 cycles (Levine, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CMF regimen:",
"     </i>",
"     Oral: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-14 every 28 days (in combination with methotrexate and fluorouracil) for 6 cycles (Levine, 1998)",
"     <b>",
"      or",
"     </b>",
"     I.V.: 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 21 days (in combination with methotrexate and fluorouracil); Goldhirsch, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic lymphocytic leukemia (unlabeled dosing):",
"     </b>",
"     I.V.: R-FC regimen: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 28 days (in combination with rituximab and fludarabine) for 6 cycles (Robak, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma (unlabeled use):",
"     </b>",
"     I.V.: VAC/IE regimen: VAC: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (plus mesna) on day 1 of a 21-day treatment cycle (in combination with vincristine and doxorubicin [then dactinomycin when maximum doxorubicin dose reached]), alternates with IE (ifosfamide and etoposide) for a total of 17 cycles (Grier, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gestational trophoblastic tumors, high-risk (unlabeled use):",
"     </b>",
"     I.V.: EMA/CO regimen: 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of 2-week treatment cycle (in combination with etoposide, methotrexate, dactinomycin, and vincristine), continue for at least 2 treatment cycles after a normal hCG level (Escobar, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granulomatosis with polyangiitis (GPA; Wegener&rsquo;s granulomatosis) (unlabeled use; in combination with glucocorticoids):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Low-dose:",
"     </i>",
"     Oral: 1.5-2 mg/kg/day (Jayne, 2003; Stone, 2010) or 2 mg/kg/day until remission, followed by 1.5 mg/kg/day for 3 additional months (de Groot, 2009; Harper, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pulse:",
"     </i>",
"     I.V.: 15 mg/kg (maximum dose: 1200 mg) every 2 weeks for 3 doses, followed by maintenance pulses of either 15 mg/kg  I.V. (maximum dose: 1200 mg) every 3 weeks or 2.5-5 mg/kg/day orally on days 1, 2, and 3 every 3 weeks for 3 months after remission achieved (de Groot, 2009; Harper, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      BEACOPP regimen:",
"     </i>",
"     650 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and prednisone) for 8 cycles (Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      BEACOPP escalated regimen:",
"     </i>",
"     1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and prednisone) for 8 cycles (Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (unlabeled dosing):",
"     </b>",
"     Oral: CyBorD regimen: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 8, 15, and 22 every 4 weeks (in combination with bortezomib and dexamethasone) for 4 cycles; may continue beyond 4 cycles (Khan, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphoma (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      R-CHOP regimen:",
"     </i>",
"     750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with rituximab, doxorubicin, vincristine, and prednisone) for 8 cycles (Coiffier, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      R-EPOCH (dose adjusted) regimen:",
"     </i>",
"     750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 5 every 3 weeks (in combination with rituximab, etoposide, prednisone, vincristine, and doxorubicin) for 6-8 cycles (Garcia-Suarez, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CODOX-M/IVAC (Burkitt&rsquo;s lymphoma):",
"     </i>",
"     Cycles 1 and 3 (CODOX-M): 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1, followed by 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 2-5 (in combination with vincristine, doxorubicin, and methotrexate); CODOX-M alternates with IVAC (etoposide, ifosfamide, and cytarabine) for a total of 4 cycles (Magrath, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis (unlabeled use):",
"     </b>",
"     I.V.: 500 mg once every 2 weeks for 6 doses or 500-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every month for 6 doses (Hahn, 2012)",
"     <b>",
"      or",
"     </b>",
"     500-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every month every month for 6 months, then every 3 months for a total of at least 2.5 years (Austin, 1986; Gourley, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transplant conditioning (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nonmyeloablative transplant (allogeneic):",
"     </i>",
"     750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days beginning 5 days prior to transplant (in combination with fludarabine) (Khouri, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Myeloablative transplant:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     100 mg/kg (based on IBW, unless actual weight &lt;95% of IBW) as a single dose 2 days prior to transplant (in combination with total body irradiation and etoposide) (Thompson, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 mg/kg/day for 4 days beginning 5 days before transplant (with or without antithymocyte globulin [equine]) (Champlin, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 mg/kg/day for 4 days beginning 5 days prior to transplant (in combination with busulfan) (Cassileth, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     60 mg/kg/day for 2 days (in combination with busulfan and total body irradiation) (Anderson, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days beginning 7 days prior to transplant (in combination with etoposide and carmustine) (Reece, 1991)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"      see \"Cyclophosphamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted. Antiemetics may be recommended (emetogenic potential varies by dose and combination therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignancy, solid tumor (single agent):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 40-50 mg/kg in divided doses over 2-5 days",
"     <b>",
"      or",
"     </b>",
"     10-15 mg/kg every 7-10 days",
"     <b>",
"      or",
"     </b>",
"     3-5 mg/kg twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-5 mg/kg/day (initial and maintenance dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nephrotic syndrome, corticosteroid refractory or intolerant:",
"     </b>",
"     Oral: 2.5-3 mg/kg/day every day for 60-90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 2-8 mg/kg (60-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) in divided doses for 6 or more days; Maintenance: 10-15 mg/kg every 7-10 days or 30 mg/kg every 3-4 weeks or when bone marrow function recovers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 2-8 mg/kg (60-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) in divided doses for 6 or more days; Maintenance: 2-5 mg/kg (50-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Indication specific and/or unlabeled uses/dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma (unlabeled use):",
"     </b>",
"     I.V.: VAC/IE regimen: VAC: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (plus mesna) on day 1 of a 21-day treatment cycle (in combination with vincristine and doxorubicin [then dactinomycin when maximum doxorubicin dose reached]), alternates with IE (ifosfamide and etoposide) for a total of 17 cycles (Grier, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma (unlabeled dosing):",
"     </b>",
"     I.V.: BEACOPP escalated regimen: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 0 of a 21-day treatment cycle (in combination with bleomycin, etoposide, doxorubicin, vincristine, prednisone, and procarbazine) for 4 cycles (Kelly, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis (unlabeled use):",
"     </b>",
"     I.V.: 500-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every month for 6 months, then every 3 months for a total of 2.5-3 years (Austin, 1986; Gourley, 1996; Lehman, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma (unlabeled dosing):",
"     </b>",
"     I.V.: CE-CAdO regimen, courses 3 and 4: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1-5 every 21 days for 2 cycles (Rubie, 1998)",
"     <b>",
"      or",
"     </b>",
"     10 mg/kg days 1-5 every 21 days for 2 cycles (Rubie, 2001).",
"     <b>",
"      Note:",
"     </b>",
"     Decreased doses may be recommended for newborns or children &lt;10 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transplant conditioning (unlabeled use):",
"     </b>",
"     Myeloablative transplant: I.V.: 50 mg/kg/day for 4 days beginning 5 days before transplant (with or without antithymocyte globulin [equine]) (Champlin, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; adjust for renal clearance.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F155462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     No adjustment provided in the manufacturer&rsquo;s  labeling (use with caution; elevated levels of metabolites may occur).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment: Dose reduction may be necessary; manufacturer&rsquo;s labeling does not provide specific dosing recommendations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      The following adjustments have also been recommended:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%); administer 50% of normal dose; administer after hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 100% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Janus, 2010: Hemodialysis: Administer 75% of normal dose; administer after hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F155463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     The pharmacokinetics of cyclophosphamide are not significantly altered in the presence of hepatic insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      The following adjustments have been recommended",
"     </i>",
"     (Floyd, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum bilirubin 3.1-5 mg/dL or transaminases &gt;3 times ULN: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum bilirubin &gt;5 mg/mL: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15163668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"     May require dose reduction or treatment interruption; Canadian labeling recommends reducing initial dose by 30% to 50% if bone marrow function compromised (due to prior radiation therapy, prior chemotherapy, or tumor infiltration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Hemorrhagic cystitis, severe:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15163732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Additional dosage forms available in Canada. Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infusion rate may vary based on protocol (refer to specific protocol for infusion rate). Administer by direct I.V. injection (if reconstituted in NS), IVPB, or continuous I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bladder toxicity: To minimize bladder toxicity, increase normal fluid intake during and for 1-2 days after cyclophosphamide dose. Most adult patients will require a fluid intake of at least 2 L/day. High-dose regimens should be accompanied by vigorous hydration with or without mesna therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematopoietic stem cell transplant: Approaches to reduction of hemorrhagic cystitis include infusion of 0.9% NaCl 3 L/m",
"     <sup>",
"      2",
"     </sup>",
"     /24 hours, infusion of 0.9% NaCl 3 L/m",
"     <sup>",
"      2",
"     </sup>",
"     /24 hours with continuous 0.9% NaCl bladder irrigation 300-1000 mL/hour, and infusion of 0.9% NaCl 1.5-3 L/m",
"     <sup>",
"      2",
"     </sup>",
"     /24 hours with intravenous mesna. Hydration should begin at least 4 hours before cyclophosphamide and continue at least 24 hours after completion of cyclophosphamide. The dose of daily mesna used may be 67% to 100% of the daily dose of cyclophosphamide. Mesna can be administered as a continuous 24-hour intravenous infusion or be given in divided doses every 4 hours. Mesna should begin at the start of treatment, and continue at least 24 hours following the last dose of cyclophosphamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Tablets are not scored and should not be cut or crushed. To minimize the risk of bladder irritation, do not administer tablets at bedtime.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F155516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, ampicillin, anidulafungin, aztreonam, bleomycin, cefazolin, cefepime, cefotaxime, cefoxitin, cefuroxime, chloramphenicol, chlorpromazine, cimetidine, cisplatin, cladribine, clindamycin, dexamethasone sodium phosphate, diphenhydramine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, erythromycin lactobionate, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hydromorphone, idarubicin, kanamycin, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, morphine, nafcillin, ondansetron, oxacillin, oxaliplatin, paclitaxel, palonosetron, pemetrexed, penicillin G potassium, piperacillin, piperacillin/tazobactam, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oncology-related uses: Treatment of Hodgkin lymphoma, non-Hodgkin lymphomas (including Burkitt's lymphoma), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphoblastic leukemia (ALL), mycosis fungoides, multiple myeloma, neuroblastoma, retinoblastoma; breast cancer; ovarian adenocarcinoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Treatment of lung cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Nononcology uses: Treatment of refractory nephrotic syndrome in children who are unresponsive or intolerant to corticosteroid therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9287820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oncology-related uses: Ewing's sarcoma, rhabdomyosarcoma, Wilms tumor, ovarian germ cell tumors, gestational trophoblastic tumors (high-risk), small cell lung cancer, testicular cancer, pheochromocytoma, hematopoietic stem cell transplant (HSCT) conditioning regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nononcology uses: Severe rheumatoid disorders, granulomatosis with polyangiitis (GPA; Wegener's granulomatosis), myasthenia gravis, multiple sclerosis, lupus nephritis, autoimmune hemolytic anemia, idiopathic thrombocytic purpura (ITP), antibody-induced pure red cell aplasia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cyclophosphamide may be confused with cycloSPORINE, ifosfamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytoxan may be confused with cefOXitin, Ciloxan&reg;, cytarabine, CytoGam&reg;, Cytosar&reg;, Cytosar-U, Cytotec&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (reversible; onset: 3-6 weeks after start of treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, azoospermia, gonadal suppression, oligospermia, oogenesis impaired, sterility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, mucositis, nausea/vomiting (dose-related), stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia (dose-related; recovery: 7-10 days after cessation), myelosuppression, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute respiratory distress syndrome, anaphylactic reactions, anaphylaxis, arrhythmias (with high-dose [HSCT] therapy), bladder/urinary fibrosis, blurred vision, cardiac tamponade (with high-dose [HSCT] therapy), cardiotoxicity, confusion, dyspnea, ejection fraction decreased, erythema multiforme, gastrointestinal hemorrhage, hearing disorders, heart block, heart failure (with high-dose [HSCT] therapy), hematuria, hemopericardium, hemorrhagic colitis, hemorrhagic myocarditis (with high-dose [HSCT] therapy), hemorrhagic ureteritis, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive liver disease), hepatitis, hepatotoxicity, hypersensitivity reactions, hyperuricemia, hypokalemia, hyponatremia, interstitial pneumonitis, interstitial pulmonary fibrosis (with high doses), jaundice, latent infection reactivation, mesenteric ischemia (acute), methemoglobinemia (with high-dose [HSCT] therapy), multiorgan failure, myocardial necrosis (with high-dose [HSCT] therapy), neurotoxicity, neutrophilic eccrine hidradenitis, ovarian fibrosis, pancreatitis, pericarditis, pigmentation changes (skin/fingernails), pneumonia, pulmonary hypertension, pulmonary infiltrates, pulmonary veno-occlusive disease, pyelonephritis, radiation recall, renal tubular necrosis, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, secondary malignancy, septic shock, sepsis, SIADH, Stevens-Johnson syndrome, testicular atrophy, thrombocytopenia (immune mediated), thrombotic disorders (arterial and venous), toxic epidermal necrolysis, toxic megacolon, tumor lysis syndrome, wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: Hypersensitivity to cyclophosphamide or any component of the formulation; severely depressed bone marrow function",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-related neutropenia is common. Thrombocytopenia and anemia may also occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiotoxicity: Cardiotoxicity has been reported, usually with high doses associated with transplant conditioning regimens, although may rarely occur with lower doses. Cardiac abnormalities do not appear to persist. Cardiotoxicities reported have included arrhythmia, congestive heart failure, heart block, hemorrhagic myocarditis, hemopericardium (secondary to hemorrhagic myocarditis and myocardial necrosis), pericarditis, and tachyarrhythmias. Cardiotoxicity is related to endothelial capillary damage; symptoms may be managed with diuretics, ACE inhibitors, beta-blockers, or inotropics (Floyd, 2005). Use with caution in patients with pre-existing cardiovascular disease. For patients with multiple cardiac risk factors, considering monitoring during treatment (Floyd, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fertility effects: May impair fertility; interferes with oogenesis and spermatogenesis. Effect on fertility is generally dependent on dose and duration of treatment and may be irreversible. The age at treatment initiation and cumulative dose were determined to be risk factors for ovarian failure in cyclophosphamide use for the treatment of systemic lupus erythematosus (SLE) (Mok, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal adverse effects: Nausea and vomiting commonly occur; premedication with antiemetics is recommended. Stomatitis/mucositis may also occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhagic cystitis: Cyclophosphamide is associated with the development of hemorrhagic cystitis; may rarely be severe and even fatal. Discontinue cyclophosphamide with severe hemorrhagic cystitis. Bladder injury is due to excretion of cyclophosphamide metabolites in the urine and appears to be dose- and treatment duration-dependent. Bladder fibrosis may also occur, either with or without cystitis. Increased hydration and frequent voiding is recommended to help prevent cystitis; some protocols utilize mesna to protect against hemorrhagic cystitis. Monitor urinalysis for hematuria. Severe or prolonged hemorrhagic cystitis may require medical or surgical treatment. Hematuria generally resolves within a few days after treatment is withheld, although it may persist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Anaphylactic reactions have been reported. Cross-sensitivity with other alkylating agents may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Monitor for infections; immunosuppression and serious infections may occur. Infections may require dose reduction, or interruption or discontinuation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicities: Pulmonary toxicities, including pneumonitis and acute respiratory distress syndrome, have been reported. Consider pulmonary function testing to assess the severity of pneumonitis (Morgan, 2011). Cyclophosphamide-induced pneumonitis is rare and may present as early (within 1-6 months) or late onset (several months to years); early onset has been reversible with discontinuation; late onset is associated with pleural thickening and may persist chronically (Malik, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Secondary malignancies (bladder cancer, myeloproliferative, and lymphoproliferative malignancies) have been reported with both single-agent and with combination chemotherapy regimens; onset may be delayed (up to several years after treatment). Bladder malignancy usually occurs in patients previously experiencing hemorrhagic cystitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing impairment: May interfere with wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be needed. Use is contraindicated in severe impairment in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be needed. Use is contraindicated in severe impairment in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anthracyclines: May potentiate the cardiotoxicity of anthracyclines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F155504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (weak/moderate), CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Cyclophosphamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etanercept: May enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: May enhance the cardiotoxic effect of Cyclophosphamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Cyclophosphamide may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days, or reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) with close monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Women of childbearing potential should avoid pregnancy while receiving cyclophosphamide treatment. Cyclophosphamide may also cause sterility in males and females (reversible in some cases). According to the National Comprehensive Cancer Network (NCCN) breast cancer guidelines (v.3.2012), chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include doxorubicin, cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks gestation, or within 3 weeks of planned delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13494888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse effects and tumorigenicity, the decision to discontinue cyclophosphamide or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F155438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be administered during or after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F155437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cyclophosphamide Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $530.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $1060.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $265.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclophosphamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $253.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $464.82",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F155424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets, BUN, UA, serum electrolytes, serum creatinine; monitor for signs/symptoms of hemorrhagic cystitis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alkyloxan (SG);",
"     </li>",
"     <li>",
"      Alkyroxan (KP);",
"     </li>",
"     <li>",
"      Ciclifen (PY);",
"     </li>",
"     <li>",
"      Cicloxal (ES);",
"     </li>",
"     <li>",
"      Cryofaxol (MX);",
"     </li>",
"     <li>",
"      Cycloblastin (AU, NZ);",
"     </li>",
"     <li>",
"      Cycloblastine (LU);",
"     </li>",
"     <li>",
"      Cyclostin (DE);",
"     </li>",
"     <li>",
"      Cyclostin N (DE);",
"     </li>",
"     <li>",
"      Cytoxan (CO, EC, HU, ID);",
"     </li>",
"     <li>",
"      Endoxan (AT, AU, BE, BG, CN, CZ, DE, EC, EE, GR, HN, HR, HU, IL, IT, LU, NL, NZ, PK, PL, PT, RU, SG, TR, UY, ZA);",
"     </li>",
"     <li>",
"      Endoxan-Asta (AE, AR, BH, CH, CY, EG, FR, HK, ID, IN, IQ, IR, JO, KW, LB, LY, MY, OM, PH, QA, SA, SY, TH, TW, YE);",
"     </li>",
"     <li>",
"      Endoxana (GB);",
"     </li>",
"     <li>",
"      Endoxon-Asta (AU);",
"     </li>",
"     <li>",
"      Enduxan (BR);",
"     </li>",
"     <li>",
"      Genoxal (BR);",
"     </li>",
"     <li>",
"      Ledoxan (PH);",
"     </li>",
"     <li>",
"      Ledoxina (MX);",
"     </li>",
"     <li>",
"      Lyophilisate (ID);",
"     </li>",
"     <li>",
"      Sendoxan (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Syklofosfamid (TR, TW);",
"     </li>",
"     <li>",
"      Xyclomed (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.48-0.71 L/kg; crosses into CSF (not in high enough concentrations to treat meningeal leukemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolites acrolein, 4-aldophosphamide, 4-hydroperoxycyclophosphamide, and nor-nitrogen mustard",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~1 hour; I.V.: Metabolites: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;30% as unchanged drug, 85% to 90% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JE, Appelbaum FR, Schoch G, et al, &ldquo;Allogeneic Marrow Transplantation for Myelodysplastic Syndrome With Advanced Disease Morphology: A Phase II Study of Busulfan, Cyclophosphamide, and Total Body-Irradiation and Analysis of Prognostic Factors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(1):220-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8558201/pubmed\" id=\"8558201\" target=\"_blank\">",
"        8558201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Austin HA 3rd, Klipel JH, Balow JE, et al, &ldquo;Therapy of Lupus Nephritis. Controlled Trial of Prednisone and Cytotoxic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 314(10):614-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/3511372/pubmed\" id=\"3511372\" target=\"_blank\">",
"        3511372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berry DL, Theriault RL, Holmes FA, et al, \"Management of Breast Cancer During Pregnancy Using a Standardized Protocol,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(3):855-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/10071276/pubmed\" id=\"10071276\" target=\"_blank\">",
"        10071276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beukelman T, Patkar NM, Saag KG, et al, &ldquo;2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2011, 63(4):465-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/21452260/pubmed\" id=\"21452260\" target=\"_blank\">",
"        21452260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonadonna G, Valagussa P, Moliterni A, et al, &ldquo;Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer: The Results of 20 Years of Follow-Up,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(14):901-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/7877646/pubmed\" id=\"7877646\" target=\"_blank\">",
"        7877646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brade W, Seeber S, and Herdrich K, &ldquo;Comparative Activity of Ifosfamide and Cyclophosphamide,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1986, 18(Suppl 2):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/3757151/pubmed\" id=\"3757151\" target=\"_blank\">",
"        3757151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassileth PA, Andersen J, Lazarus HM, et al, &ldquo;Autologous Bone Marrow Transplant in Acute Myeloid Leukemia in First Remission,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(2):314-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8426209/pubmed\" id=\"8426209\" target=\"_blank\">",
"        8426209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Champlin RE, Perez WS, Passweg JR, et al, &ldquo;Bone Marrow Transplantation for Severe Aplastic Anemia: A Randomized Controlled Study of Conditioning Regimens,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(10):4582-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/17272503/pubmed\" id=\"17272503\" target=\"_blank\">",
"        17272503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang C, Storer BE, Scott BL, et al, &ldquo;Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome: Similar Outcomes in Patients With De Novo Disease and Disease Following Prior Therapy or Antecedent Hematologic Disorders,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(4):1379-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/17488876/pubmed\" id=\"17488876\" target=\"_blank\">",
"        17488876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Lepage E, Briere J, et al, &ldquo;CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(4):235-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/11807147 /pubmed\" id=\"11807147 \" target=\"_blank\">",
"        11807147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deeg HJ, Shulman HM, Anderson JE, et al, &ldquo;Allogeneic and Syngeneic Marrow Transplantation for Myelodysplastic Syndrome in Patients 55 to 66 Years of Age,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2000, 95 (4):1188-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/10666189/pubmed\" id=\"10666189\" target=\"_blank\">",
"        10666189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot K, Harper L, Jayne DR, et al, &ldquo;Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(10):670-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/19451574/pubmed\" id=\"19451574\" target=\"_blank\">",
"        19451574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonge ME, Huitema AD, van Dam SM, et al, &ldquo;Significant Induction of Cyclophosphamide and Thiotepa Metabolism by Phenytoin,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2005, 55(5):507-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/15685452/pubmed\" id=\"15685452\" target=\"_blank\">",
"        15685452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeLeve LD, Shulman HM, and McDonald GB, \"Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease),\"",
"      <i>",
"       Semin Liver Dis",
"      </i>",
"      , 2002, F22(1):27-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/11928077/pubmed\" id=\"11928077\" target=\"_blank\">",
"        11928077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, \"Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eder JP, Elias A, Shea TC, et al, &ldquo;A Phase I-II Study of Cyclophosphamide, Thiotepa, and Carboplatin With Autologous Bone Marrow Transplantation in Solid Tumor Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(7):1239-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/2162912/pubmed\" id=\"2162912\" target=\"_blank\">",
"        2162912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escobar PF, Lurain JR, Singh DK, et al, &ldquo;Treatment of High-Risk Gestational Trophoblastic Neoplasia With Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine Chemotherapy,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2003, 91(3):552-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/14675675/pubmed\" id=\"14675675\" target=\"_blank\">",
"        14675675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher B, Brown AM, Dimitrov NV, et al, &ldquo;Two Months of Doxorubicin-Cyclophosphamide With and Without Interval Reinduction Therapy Compared With 6 Months of Cyclophosphamide, Methotrexate, and Fluorouracil in Positive-Node Breast Cancer Patients With Tamoxifen-Nonresponsive Tumors: Results From the National Surgical Adjuvant Breast and Bowel Project B-15,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(9):1483-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/2202791 /pubmed\" id=\"2202791 \" target=\"_blank\">",
"        2202791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraiser LH, Kanekal S, and Kehrer JP, &ldquo;Cyclophosphamide Toxicity. Characterizing and Avoiding the Problem,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(5):781-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/1723374/pubmed\" id=\"1723374\" target=\"_blank\">",
"        1723374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garc&iacute;a-Su&aacute;rez J, Ba&ntilde;as H, Arribas I, et al, \"Dose-Adjusted EPOCH Plus Rituximab is an Effective Regimen in Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Lymphoma: Results From a Prospective Observational Study,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2007, 136(2):276-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/17233819 /pubmed\" id=\"17233819 \" target=\"_blank\">",
"        17233819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giralt SA, LeMaistre CF, Vriesendorp HM, et al, &ldquo;Etoposide, Cyclophosphamide, Total-Body Irradiation and Allogeneic Bone Marrow Transplantation for Hematologic Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(9):1923-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8083714/pubmed\" id=\"8083714\" target=\"_blank\">",
"        8083714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glynn SA, Boersma BJ, Howe TM, et al, &ldquo;A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated With Cyclophosphamide,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(12):4165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/19509150/pubmed\" id=\"19509150\" target=\"_blank\">",
"        19509150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldhirsch A, Colleoni M, Coates AS, et al, &ldquo;Adding Adjuvant CMF Chemotherapy to Either Radiotherapy or Tamoxifen: Are All CMFs Alike? The International Breast Cancer Study Group (IBCSG),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1998, 9(5):489-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/9653488/pubmed\" id=\"9653488\" target=\"_blank\">",
"        9653488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gourley MF, Austin HA 3rd, Scott D, et al, &ldquo;Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients With Lupus Nephritis. A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1996, 125(7):549-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8815753/pubmed\" id=\"8815753\" target=\"_blank\">",
"        8815753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green DM, Cotton CA, Malogolowkin M, et al, &ldquo;Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2007, 48(5):493-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/16547940/pubmed\" id=\"16547940\" target=\"_blank\">",
"        16547940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, &ldquo;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahn BH, McMahon MA, Wilkinson A, et al, \"American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,\"",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(6):797-808.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/22556106/pubmed\" id=\"22556106\" target=\"_blank\">",
"        22556106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahn KM, Johnson PH, Gordon N, et al, \"Treatment of Pregnant Breast Cancer Patients and Outcomes of Children Exposed to Chemotherapy",
"      <i>",
"       In utero",
"      </i>",
"      ,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 107(6):1219-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/16894524/pubmed\" id=\"16894524\" target=\"_blank\">",
"        16894524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper L, Morgan MD, Walsh M, et al, &ldquo;Pulse versus Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: Long-Term Follow-up,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2012, 71(6):955-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/22128076/pubmed\" id=\"22128076\" target=\"_blank\">",
"        22128076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 27(1):127-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/19018081/pubmed\" id=\"19018081\" target=\"_blank\">",
"        19018081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al, &ldquo;Wegener Granulomatosis: An Analysis of 158 Patients,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1992, 116(6):488-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/1739240/pubmed\" id=\"1739240\" target=\"_blank\">",
"        1739240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, \"Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jayne D, Rasmussen N, Andrassy K, et al, &ldquo;A randomized Trial of Maintenance Therapy for Vasculitis Associated With Antineutrophil Cytoplasmic Autoantibodies,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(1):36-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/12840090/pubmed\" id=\"12840090\" target=\"_blank\">",
"        12840090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(3): 547-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/10653870 /pubmed\" id=\"10653870 \" target=\"_blank\">",
"        10653870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MJ, O'Brien S, Albitar M, et al, &ldquo;Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2005, 23(18):4079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/15767648 /pubmed\" id=\"15767648 \" target=\"_blank\">",
"        15767648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, Sposto R, Hutchinson R, et al, &ldquo;BEACOPP Chemotherapy is a Highly Effective Regimen in Children and Adolescents With High-Risk Hodgkin lymphoma: A Report from the Children&rsquo;s Oncology Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(9):2596-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/21079154/pubmed\" id=\"21079154\" target=\"_blank\">",
"        21079154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan ML, Reeder CB, Kumar SK, et al, &ldquo;A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 156(3):326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/22107129/pubmed\" id=\"22107129\" target=\"_blank\">",
"        22107129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khouri IF, McLaughlin P, Saliba RM, et al, &ldquo;Eight-Year Experience With Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma After Nonmyeloablative Conditioning With Fludarabine, Cyclophosphamide, and Rituximab,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(12):5530-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/18411419/pubmed\" id=\"18411419\" target=\"_blank\">",
"        18411419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2607-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/7527454 /pubmed\" id=\"7527454 \" target=\"_blank\">",
"        7527454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langford CA, &ldquo;Complications of Cyclophosphamide Therapy,&rdquo;",
"      <i>",
"       Eur Arch Otorhinolaryngol",
"      </i>",
"      , 1997, 254(2):65-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/9065658/pubmed\" id=\"9065658\" target=\"_blank\">",
"        9065658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/7718875/pubmed\" id=\"7718875\" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lehman TJ and Onel K, &ldquo;Intermittent Intravenous Cyclophosphamide Arrests Progression of the Renal Chronicity Index in Childhood Systemic Lupus Erythematosus,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 136(2):243-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/10657833/pubmed\" id=\"10657833\" target=\"_blank\">",
"        10657833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine MN, Bramwell VH, Pritchard KI, et al, &ldquo;Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer. National Cancer Institute of Canada Clinical Trials Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(8):2651-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/9704715/pubmed\" id=\"9704715\" target=\"_blank\">",
"        9704715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magrath I, Adde M, Shad A, et al, \"Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(3):925-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8622041/pubmed\" id=\"8622041\" target=\"_blank\">",
"        8622041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malik SW, Myers JL, DeRemee RA, et al, &ldquo;Lung Toxicity Associated With Cyclophosphamide Use. Two Distinct Patterns,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1996, 154(6 Pt 1):1851-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/8970380/pubmed\" id=\"8970380\" target=\"_blank\">",
"        8970380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mok CC, Lau CS, and Wong RW, &ldquo;Risk Factors for Ovarian Failure in Patients With Systemic Lupus Erythematosus Receiving Cyclophosphamide Therapy,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41(5):831-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/9588734/pubmed\" id=\"9588734\" target=\"_blank\">",
"        9588734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, \"Management of Uncommon Chemotherapy-Induced Emergencies,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murdych T and Weisdorf DJ, &ldquo;Serious Cardiac Complications During Bone Marrow Transplantation at the University of Minnesota, 1977-1997,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2001, 28(3):283-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/11535997/pubmed\" id=\"11535997\" target=\"_blank\">",
"        11535997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 3.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petri M, Brodsky RA, Jones RJ, et al, &ldquo;High-Dose Cyclophosphamide versus Monthly Intravenous Cyclophosphamide for Systemic Lupus Erythematosus: A Prospective Randomized Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2010, 62(5):1487-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/20131296/pubmed\" id=\"20131296\" target=\"_blank\">",
"        20131296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reece DE, Barnett MJ, Connors JM, et al, &ldquo;Intensive Chemotherapy With Cyclophosphamide, Carmustine, and Etoposide Followed by Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1991, 9(10):1871-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/1919637/pubmed\" id=\"1919637\" target=\"_blank\">",
"        1919637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robak T, Dmoszynska A, Solal-C&eacute;ligny P, et al, &ldquo;Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(10):1756-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/20194844/pubmed\" id=\"20194844\" target=\"_blank\">",
"        20194844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1998, 77(12):2310-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/9649151 /pubmed\" id=\"9649151 \" target=\"_blank\">",
"        9649151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Plantaz D, Coze C, et al, \"Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,\"",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 2001, 36(1):247-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/11464897/pubmed\" id=\"11464897\" target=\"_blank\">",
"        11464897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuchter LM, Hensley ML, Meropol NJ, et al, &ldquo;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/12065567/pubmed\" id=\"12065567\" target=\"_blank\">",
"        12065567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sehn LH, Antin JH, Shulman LN, et al, &ldquo;Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 91(2):717-23.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shehadeh N, Dansey R, Seen S, et al, &ldquo;Cyclophosphamide-Induced Methemoglobinemia,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 32(11):1109-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/14625586/pubmed\" id=\"14625586\" target=\"_blank\">",
"        14625586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snowden JA, Pearce RM, Lee J, et al, \"Haematopoietic Stem Cell Transplantation (HSCT) in Severe Autoimmune Diseases: Analysis of UK Outcomes From the British Society of Blood and Marrow Transplantation (BSBMT) Data Registry 1997-2009,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 157(6):742-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/22533715/pubmed\" id=\"22533715\" target=\"_blank\">",
"        22533715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snowden JA, Saccardi R, Allez M, et al, \"Haematopoietic SCT in Severe Autoimmune Diseases: Updated Guidelines of the European Group for Blood and Marrow Transplantation,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2012, 47(6):770-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/22002489/pubmed\" id=\"22002489\" target=\"_blank\">",
"        22002489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone JH, Merkel PA, Spiera R, et al, &ldquo;Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(3):221-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/20647199/pubmed\" id=\"20647199\" target=\"_blank\">",
"        20647199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson JA, Fisher RI, Leblanc M, et al, &ldquo;Total Body Irradiation, Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem-Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin Lymphoma: Results of a Phase 3 Randomized Trial by the Southwest Oncology Group (SWOG 9438),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(8):4048-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/18256325/pubmed\" id=\"18256325\" target=\"_blank\">",
"        18256325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheeler C, Antin JH, Churchill WH, et al, &ldquo;Cyclophosphamide, Carmustine and Etoposide With Autologous Bone Marrow Transplantation in Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma: A Dose-Finding Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, (4):648-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/2313334/pubmed\" id=\"2313334\" target=\"_blank\">",
"        2313334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xie H, Griskevicius L, Stahle L, et al, &ldquo;Pharmacogenetics of Cyclophosphamide in Patients With Hematologic Malignancies,&rdquo;",
"      <i>",
"       Eur J Pharm Sci",
"      </i>",
"      , 2006, 27(1):54-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/20/9546/abstract-text/16183265/pubmed\" id=\"16183265\" target=\"_blank\">",
"        16183265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9308 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9546=[""].join("\n");
var outline_f9_20_9546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155510\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155460\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155487\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155461\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155462\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155463\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163668\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155426\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163732\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155411\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155430\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155516\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155429\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9287820\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155519\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155508\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155434\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155415\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155420\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155451\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155422\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494887\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155473\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494888\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155438\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155437\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155424\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155439\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155414\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155433\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6550?source=related_link\">",
"      Cyclophosphamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=related_link\">",
"      Cyclophosphamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_20_9547="Ogilvies syndrome associations";
var content_f9_20_9547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common clinical conditions associated with Ogilvie's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Trauma, especially fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstetrical surgery, especially involving spinal anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic, abdominal, or cardiothoracic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major orthopedic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe medical illness, such as pneumonia, myocardial infarction, or heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal pathology, such as malignancy or hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One of the above",
"        <strong>",
"         plus",
"        </strong>",
"        metabolic imbalance or medication administration (eg, narcotics, phenothiazines, calcium channel blockers, alpha-2-adrenergic agonists, epidural analgesics)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9547=[""].join("\n");
var outline_f9_20_9547=null;
var title_f9_20_9548="DMD pre anesthesia";
var content_f9_20_9548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the evaluation and management of patients with Duchenne muscular dystrophy (DMD) before general anesthesia or procedural sedation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obtain anesthesiology and pulmonology consultations before procedures involving general anesthesia or procedural sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Perform a pulmonary evaluation that includes measurement of forced vital capacity (FVC), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), peak cough flow (PCF), and oxyhemoglobin saturation measured by pulse oximetry (SpO2) in room air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Measure the blood and/or end-tidal carbon dioxide level if SpO2 is &lt;95 percent in room air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; For patients with DMD who are at increased risk of respiratory complications, defined by an FVC &lt;50 percent of predicted, and especially for patients at high risk for complications, defined by an FVC &lt;30 percent of predicted, consider preoperative training in the use of noninvasive positive pressure ventilation (NPPV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; For patients at high risk of ineffective cough, defined in adults by PCF &lt;270 L/min or MEP &lt;60 cmH2O, consider preoperative training in manual and mechanically assisted cough, emphasizing use of mechanical insufflation-exsufflation with a bronchial secretion clearance device (eg, CoughAssist)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Refer the patient to a cardiologist for clinical evaluation and optimization of cardiac therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obtain a nutritional assessment, optimize nutritional status, and consider strategies to manage dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Discuss the risks and benefits of general anesthesia or procedural sedation with the patient and guardians, and help them to decide on and implement their decisions regarding resuscitation parameters and, if applicable, advance directives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Birnkrant, DJ, Panitch, HB, Benditt, JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9548=[""].join("\n");
var outline_f9_20_9548=null;
var title_f9_20_9549="Evaluation shoulder pain";
var content_f9_20_9549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential history and examination of the shoulder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        History and epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examination findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likely diagnosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Generally age &gt;40",
"        </p>",
"        <p>",
"         Pain increases with reaching",
"        </p>",
"        Frequent repetitive activity at or above shoulder",
"       </td>",
"       <td>",
"        <p>",
"         Subacromial tenderness",
"        </p>",
"        <p>",
"         Pain with Apley scratch tests",
"        </p>",
"        <p>",
"         Normal passive range of motion",
"        </p>",
"        <p>",
"         Normal strength but pain with testing midarc abduction and/or external rotation",
"        </p>",
"        Pain with impingement testing (Neer and Hawkins tests)",
"       </td>",
"       <td>",
"        Rotator cuff tendinopathy (very common)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Same as rotator cuff tendinopathy, but weakness present",
"        </p>",
"        Midde aged and older",
"       </td>",
"       <td>",
"        Same as rotator cuff tendinopathy but weakness often present with resisted abduction and/or external rotation",
"       </td>",
"       <td>",
"        Rotator cuff tear",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Past history of rotator cuff tendinopathy, diabetes, or immobility for any reason",
"        </p>",
"        Complaint of decreased motion +/- pain",
"       </td>",
"       <td>",
"        Significant decrease in range of motion, both active and passive",
"       </td>",
"       <td>",
"        Adhesive capsulitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Past history of shoulder trauma",
"       </td>",
"       <td>",
"        Decrease in range of motion - both active and passive",
"       </td>",
"       <td>",
"        Glenohumoral osteoarthritis (uncommon)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Pain increases when carrying objects with elbows bent (eg, shopping bags) or lifting overhead",
"       </td>",
"       <td>",
"        <p>",
"         Bicipital groove tenderness",
"        </p>",
"        Pain with resisted elbow flexion or supination",
"       </td>",
"       <td>",
"        Biceps tendinopathy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Sudden increase in shoulder pain with \"Popeye\" deformity (ie, prominent ipsilateral distal bicep)",
"       </td>",
"       <td>",
"        <p>",
"         Obvious biceps deformity",
"        </p>",
"        Pain with resisted elbow flexion or supination",
"       </td>",
"       <td>",
"        Biceps tendon rupture",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Recent fall onto adducted arm",
"        </p>",
"        Focal AC joint pain",
"       </td>",
"       <td>",
"        <p>",
"         AC joint tenderness with possible stepoff",
"        </p>",
"        <p>",
"         Pain with adduction of injured arm",
"        </p>",
"        Clavicle elevation on x-ray with higher grade sprain",
"       </td>",
"       <td>",
"        Acromioclavicular injury",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Focal AC joint pain without recent trauma",
"       </td>",
"       <td>",
"        <p>",
"         AC joint tenderness",
"        </p>",
"        Pain with adduction of injured arm",
"       </td>",
"       <td>",
"        Acromioclavicular osteoarthritis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Generally age &lt;40",
"        </p>",
"        <p>",
"         Overhead athletes",
"        </p>",
"        Nonspecific symptoms",
"       </td>",
"       <td>",
"        <p>",
"         Sulcus test shows increased motion",
"        </p>",
"        Apprehension, relocation, and release tests positive",
"       </td>",
"       <td>",
"        Multidirectional shoulder instability (may have concomitant rotator cuff tear)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Poor muscular development, frequent repetitive to-and-fro motion (eg, ironing), and direct pressure (eg, backpack) are common causes",
"       </td>",
"       <td>",
"        Superiomedial scapular border tender (performed with ipsilateral arm adducted)",
"       </td>",
"       <td>",
"        Subscapular bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedentary (eg, works at desk job); poor posture with rounded upper back",
"       </td>",
"       <td>",
"        <p>",
"         Abnormal, uncoordinated scapulothoracic and glenohumoral motion",
"        </p>",
"        <p>",
"         Wall push off may reveal mild scapular winging",
"        </p>",
"        Stabilization of scapula by examiner improves shoulder strength",
"       </td>",
"       <td>",
"        Scapular stabilizer muscle weakness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9549=[""].join("\n");
var outline_f9_20_9549=null;
var title_f9_20_9550="TNF-alpha inhibitors and TB";
var content_f9_20_9550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cumulative proportion of tuberculosis cases reported to the US Food and Drug Administration in patients treated with TNF- alpha inhibitors in relation to duration of anti-TNF therapy.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 334px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     TNF: Tumor necrosis factor",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wallis, RS, Broder, M, Wong, J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41:S194. Copyright &copy; 2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9550=[""].join("\n");
var outline_f9_20_9550=null;
var title_f9_20_9551="Secretin tissue distribution";
var content_f9_20_9551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Location of secretin-producing cells throughout the gastrointestinal tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_20_9551=[""].join("\n");
var outline_f9_20_9551=null;
